BBS-Bioactive Bone Substitutes Plc: The patent regarding the product ARTEBONE® has been granted in the USA

BBS-Bioactive Bone Substitutes Plc’s patent application ”A METHOD FOR PREPARING A BONE PROTEIN PREPARATION AND A BONE PROTEIN PREPARATION” for the product has been accepted in the USA. The company’s product ARTEBONE® is now patented in all countries where it has been applied for. The patent application regarding the production is still in progress in the USA. 

CEO Ilkka Kangasniemi:
”The USA is the most significant market of orthopaedic products. Thus, this news about the patent approval is very remarkable for our company. Now the ARTEBONE® product and its unique component, bone protein extract, are protected by patents around all major market areas globally.”

More information:
Ilkka Kangasniemi, CEO, tel. +358 40 7080 307, e-mail:
Certified Adviser: Certified Advisers AB, +46 70 5516 729,

Nasdaq Helsinki Oy
Nasdaq Stockholm AB
Main Media

This is information that BBS-Bioactive Bone Substitutes Plc is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on 7th April 2020 at 4:00 pm (UTC+3:00).

BBS-Bioactive Bone Substitutes Plc is a Finnish orthobiologic biotech company. We have developed a new product for healing of difficult bone fractures and for solving the problems in bone healing. Our mission is to offer new generation medicinal products for the orthopedic surgery. The research and development in the field of medicine requires perseverance and courage to develop new things.  We have over 20 years of expertise in this. Our operations are characterised by top expertise, innovativeness and dedicated and committed employees. The first product, ARTEBONE® paste, is ready and the application process for the CE-marking enabling commercialization is in progress.

More information: